Abbott Laboratories 관리
관리 기준 확인 3/4
Abbott Laboratories CEO는 Robert Ford, Oct2018 에 임명되었습니다 의 임기는 6.08 년입니다. 총 연간 보상은 $ 23.27M, 6.4% 로 구성됩니다. 6.4% 급여 및 93.6% 보너스(회사 주식 및 옵션 포함). 는 $ 49.32M 가치에 해당하는 회사 주식의 0.024% 직접 소유합니다. 49.32M. 경영진과 이사회의 평균 재임 기간은 각각 5.5 년과 5.8 년입니다.
주요 정보
Robert Ford
최고 경영자
US$23.3m
총 보상
| CEO 급여 비율 | 6.4% |
| CEO 임기 | 6.1yrs |
| CEO 소유권 | 0.02% |
| 경영진 평균 재임 기간 | 5.5yrs |
| 이사회 평균 재임 기간 | 5.8yrs |
최근 관리 업데이트
Recent updates
Abbott Laboratories: Investors Should Wait For A Pullback
Nov 25Investors Will Want Abbott Laboratories' (NYSE:ABT) Growth In ROCE To Persist
Oct 31
Abbott Laboratories: Long-Term Optimism, Short-Term Overvaluation
Oct 21Abbott: Challenging Comparables, Unappealing Value Limit The Incentive To Go Long Ahead Of Q3 Event
Oct 14Does Abbott Laboratories (NYSE:ABT) Have A Healthy Balance Sheet?
Oct 11Why We're Not Concerned About Abbott Laboratories' (NYSE:ABT) Share Price
Sep 27Abbott Laboratories: Cardiovascular Disease Has Been A Tailwind, But Things Could Change
Sep 11A Look At The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)
Aug 16Abbott Laboratories: Driving Value By Scaling Innovations
Aug 13Abbott Laboratories: A Strong Healthcare Stock For Long-Term Dividend Growth Investors
Aug 05Abbott Laboratories: When Double-Digit Device Growth Apparently Isn't Enough
Jul 13These 4 Measures Indicate That Abbott Laboratories (NYSE:ABT) Is Using Debt Reasonably Well
Jul 01Abbott Laboratories (NYSE:ABT) Is Doing The Right Things To Multiply Its Share Price
Jun 18Investors Still Waiting For A Pull Back In Abbott Laboratories (NYSE:ABT)
Jun 04Abbott Laboratories: Why I Agree With Wall Street On This One
Jun 04Abbott Laboratories: Buying More Of This Top-Notch Dividend Growth Stock
May 18Abbott Laboratories: Organic Growth Will Be Key To Q1 Earnings
Apr 17Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)
Apr 15Abbott Laboratories: Buy This World-Class Dividend Growth Stock Now
Mar 21Abbott Laboratories (NYSE:ABT) Might Have The Makings Of A Multi-Bagger
Mar 19Here's Why Abbott Laboratories (NYSE:ABT) Can Manage Its Debt Responsibly
Mar 06Abbott Labs' Reversal Is Here - CGM Tailwinds In 2024
Feb 27Abbott Laboratories' (NYSE:ABT) Shares May Have Run Too Fast Too Soon
Feb 08The King Is Back: Abbott Laboratories' Path To >11% Annual Returns
Jan 29The Abbott Laboratories (NYSE:ABT) Full-Year Results Are Out And Analysts Have Published New Forecasts
Jan 26CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$6b |
| Jun 30 2024 | n/a | n/a | US$6b |
| Mar 31 2024 | n/a | n/a | US$6b |
| Dec 31 2023 | US$23m | US$2m | US$6b |
| Sep 30 2023 | n/a | n/a | US$5b |
| Jun 30 2023 | n/a | n/a | US$5b |
| Mar 31 2023 | n/a | n/a | US$6b |
| Dec 31 2022 | US$22m | US$2m | US$7b |
| Sep 30 2022 | n/a | n/a | US$8b |
| Jun 30 2022 | n/a | n/a | US$9b |
| Mar 31 2022 | n/a | n/a | US$8b |
| Dec 31 2021 | US$25m | US$1m | US$7b |
| Sep 30 2021 | n/a | n/a | US$7b |
| Jun 30 2021 | n/a | n/a | US$6b |
| Mar 31 2021 | n/a | n/a | US$6b |
| Dec 31 2020 | US$20m | US$1m | US$4b |
| Sep 30 2020 | n/a | n/a | US$3b |
| Jun 30 2020 | n/a | n/a | US$3b |
| Mar 31 2020 | n/a | n/a | US$4b |
| Dec 31 2019 | US$12m | US$1m | US$4b |
| Sep 30 2019 | n/a | n/a | US$3b |
| Jun 30 2019 | n/a | n/a | US$3b |
| Mar 31 2019 | n/a | n/a | US$3b |
| Dec 31 2018 | US$8m | US$784k | US$2b |
| Sep 30 2018 | n/a | n/a | US$802m |
| Jun 30 2018 | n/a | n/a | US$812m |
| Mar 31 2018 | n/a | n/a | US$365m |
| Dec 31 2017 | US$5m | US$675k | US$344m |
보상 대 시장: Robert 의 총 보상 ($USD 23.27M )은 US 시장( $USD 12.64M ).
보상과 수익: Robert 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.
CEO
Robert Ford (50 yo)
6.1yrs
테뉴어
US$23,268,171
보상
Mr. Robert B. Ford has been the Chief Executive Officer of Abbott Laboratories since March 31, 2020 and also serves as its Chairman of the Board since December 10, 2021. He has been President at Abbott Lab...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Chairman of the Board | 6.1yrs | US$23.27m | 0.024% $ 49.3m | |
| CFO & Executive VP of Finance | 1.2yrs | US$3.32m | 0.0023% $ 4.7m | |
| Executive VP | 11.8yrs | US$7.42m | 0.011% $ 21.8m | |
| Executive VP and Group President of Established Pharmaceuticals & Nutritional Products | 10.2yrs | US$5.93m | 0.0073% $ 14.9m | |
| Executive VP & Group President of Medical Devices | 5.8yrs | US$5.50m | 0.0035% $ 7.3m | |
| Senior VP of Business & Technology Services and Chief Information Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| Vice President of Investor Relations. | no data | 데이터 없음 | 데이터 없음 | |
| VP and Chief Ethics & Compliance Officer | no data | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Commercial Operations | 1.8yrs | 데이터 없음 | 데이터 없음 | |
| Executive Vice President of Human Resources | 5.3yrs | 데이터 없음 | 0.0059% $ 12.1m | |
| Senior Vice President of Global Marketing & External Affairs | no data | 데이터 없음 | 데이터 없음 | |
| Executive Vice President of Diabetes Care | 9.4yrs | 데이터 없음 | 0.0042% $ 8.5m |
5.5yrs
평균 재임 기간
54yo
평균 연령
경험이 풍부한 관리: ABT 의 관리팀은 노련하고 경험 (평균 재직 기간 5.5 년)입니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Chairman of the Board | 5yrs | US$23.27m | 0.024% $ 49.3m | |
| Independent Director | 7.8yrs | US$349.29k | 0.39% $ 792.7m | |
| Independent Director | 7.8yrs | US$341.96k | 0.00020% $ 409.8k | |
| Lead Independent Director | 12.9yrs | US$405.96k | 0.00027% $ 553.2k | |
| Independent Director | 3.6yrs | US$337.96k | 0% $ 0 | |
| Independent Director | 16.1yrs | US$441.44k | 0% $ 0 | |
| Independent Director | 1.6yrs | US$283.96k | 0% $ 0 | |
| Independent Director | 6.4yrs | US$331.96k | 0.00018% $ 368.8k | |
| Independent Director | 12.9yrs | US$362.60k | 0.00015% $ 307.3k | |
| Independent Director | 2.2yrs | US$354.96k | 0% $ 0 | |
| Independent Director | 5.2yrs | US$331.19k | 0% $ 0 | |
| Independent Director | 3.3yrs | US$356.96k | 0% $ 0 |
5.8yrs
평균 재임 기간
62yo
평균 연령
경험이 풍부한 이사회: ABT 의 이사회는 경험(평균 재직 기간 5.8 년)으로 간주됩니다.